Clinical trial
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
NCT03275454 is registered in ClinicalTrials.gov with Bioverativ, a Sanofi company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
- Lead sponsor
- Bioverativ, a Sanofi company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 14, 2017
- Completion date
- February 16, 2021
- Enrollment
- 12 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.